Abstract
Colorectal cancer is a common malignancy in the United States and a significant cause of mortality yearly. Most recently, target-directed therapies have been added to the armamentarium. These include agents directed at the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). These agents improve survival in some patients; however, they are associated with high costs and increased toxicities. It is, therefore, necessary for a biomarker to be developed to enrich the patient population receiving these agents. Numerous potential biomarkers have been investigated including EGFR copy number, EGFR mutations, PTEN, AKT, KRAS, and the development of the acneiform rash. Here we review the data on KRAS mutation status and the response to treatment of patients with metastatic colorectal cancer (mCRC). These patients have received the EGFR-directed agents, cetuximab and panitumumab. In addition, a cost analysis is also performed to determine the cost effectiveness of KRAS mutation analysis.
Keywords: Cetuximab, panitumumab, EGFR, KRAS, colorectal cancer.
Current Cancer Therapy Reviews
Title:KRAS Mutation Analysis Prior to EGFR-Directed Therapy for Metastatic Colorectal Cancer: A Review and Cost Analysis
Volume: 6 Issue: 4
Author(s): Dustin Deming and Kyle Holen
Affiliation:
Keywords: Cetuximab, panitumumab, EGFR, KRAS, colorectal cancer.
Abstract: Colorectal cancer is a common malignancy in the United States and a significant cause of mortality yearly. Most recently, target-directed therapies have been added to the armamentarium. These include agents directed at the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). These agents improve survival in some patients; however, they are associated with high costs and increased toxicities. It is, therefore, necessary for a biomarker to be developed to enrich the patient population receiving these agents. Numerous potential biomarkers have been investigated including EGFR copy number, EGFR mutations, PTEN, AKT, KRAS, and the development of the acneiform rash. Here we review the data on KRAS mutation status and the response to treatment of patients with metastatic colorectal cancer (mCRC). These patients have received the EGFR-directed agents, cetuximab and panitumumab. In addition, a cost analysis is also performed to determine the cost effectiveness of KRAS mutation analysis.
Export Options
About this article
Cite this article as:
Deming Dustin and Holen Kyle, KRAS Mutation Analysis Prior to EGFR-Directed Therapy for Metastatic Colorectal Cancer: A Review and Cost Analysis, Current Cancer Therapy Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339410793358101
DOI https://dx.doi.org/10.2174/157339410793358101 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials
Clinical Cancer Drugs Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design The Anti-Inflammatory and Pharmacological Actions of Oleocanthal, a Phenolic Contained in Extra Virgin Olive Oil
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis of New Curcumin-like Pentadienones by O- and C-glycosylation
Current Organic Chemistry Proline-Directed Protein Kinase FA as a Potential Target for Diagnosis and Therapy of Human Cancers
Current Cancer Drug Targets Cancer Microbiome; Opportunities and Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
Current Topics in Medicinal Chemistry Can Colorectal Cancer be Prevented or Treated by Oral Hormone Replacement Therapy?
Current Molecular Pharmacology [6]-gingerol as a Cancer Chemopreventive Agent: A Review of Its Activity on Different Steps of the Metastatic Process
Mini-Reviews in Medicinal Chemistry Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Colon Targeted Liposomal Systems (CTLS): Theranostic Potential
Current Molecular Medicine Oncogenomics
Current Drug Metabolism Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Investigation of Methylene Blue Release from Functional Polymeric Systems Using Dielectric Analysis
Current Drug Delivery The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives
Anti-Cancer Agents in Medicinal Chemistry Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology